EUCTR2018-000268-26-DK
进行中（未招募）
1 期
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
AbbVie Deutschland0 个研究点目标入组 400 人2019年10月1日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Alzheimer's Disease
- 发起方
- AbbVie Deutschland
- 入组人数
- 400
- 状态
- 进行中（未招募）
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Subject has voluntarily provided written informed consent
- •Subject completed the 96\-week treatment period of Study M15\-566\.
- •Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities.
- •The study partner has provided written informed consent.
- •If female, subject must be postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
- •If the male subject is sexually active with female partner(s) of childbearing potential, he must agree, from Study Day 1 through 20 weeks after the last dose of study drug to practice the protocol specified contraception and must refrain from sperm donation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 120
排除标准
- •Subject has any significant change in his/her medical condition since participation in Study M15\-566 that could interfere with the subject's participation in Study M15\-570, could place the subject at increased risk, or could confound interpretation of study results. This would include any clinically significant neurological, hematological, autoimmune, endocrine, cardiovascular, neoplastic, renal, hepatic, metabolic, psychiatric, pulmonary, gastrointestinal, or other major disorder or contraindication to or inability to tolerate brain MRI or PET scans.
- •More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15\-566\.
- •Subject is concurrently enrolled in another interventional clinical study (with the exception of Study M15\-566\) involving a therapeutic agent.
- •Subject is considered by the investigator to be an unsuitable candidate to receive ABBV\-8E12 or the subject is considered by the investigator to be unable or unlikely to comply with the dosing schedule or study evaluations.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
An extension study to continue evaluating the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's diseaseAlzheimer's DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2018-000268-26-ITABBVIE DEUTSCHLAND GMBH & CO. KG400
进行中（未招募）
1 期
An extension study to continue evaluating the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's diseaseEUCTR2018-000268-26-ESAbbVie Deutschland400
撤回
2 期
An Extension Study of ABBV-8E12 in Early Alzheimer's DiseaseneurologischAlzheimer'sAlzheimer's diseaseNL-OMON49765AbbVie Deutschland GmbH & Co. KG7
进行中（未招募）
1 期
An extension study to continue evaluating the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's diseaseAlzheimer's DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2018-000268-26-BEAbbVie Deutschland400
进行中（未招募）
1 期
An extension study to continue evaluating the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's diseaseAlzheimer's DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2018-000268-26-FIAbbVie Deutschland400